Citation Impact
Citing Papers
Evolution of the Cancer Stem Cell Model
2014 Standout
Romidepsin: a novel histone deacetylase inhibitor for cancer
2011
Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia
2010
The Role of Phenolic Compounds in the Fight against Cancer – A Review
2013
Natural products: An evolving role in future drug discovery
2011 Standout
Niemann-Pick disease type C
2010 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
2010
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
IgG4-related disease
2014 Standout
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
2009
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
Panobinostat in lymphoid and myeloid malignancies
2013
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Immunoglobulin G4-related diseases in the head and neck: A systematic review
2015
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
2009
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
2010
Natural product and natural product derived drugs in clinical trials
2014 Standout
Histone Deacetylase Inhibitors in Cancer Therapy
2009
Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts
2011
Panobinostat (LBH589): A Potent Pan-Deacetylase Inhibitor with Promising Activity Against Hematologic and Solid Tumors
2009
CutaneousT ‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management
2015
How I treat mycosis fungoides and Sézary syndrome
2016
2015
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of Chris McCormack being referenced
Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
2008
2013